Influence of intracerebral administration of NO agents in dorsal hippocampus (CA1) on cannabinoid state-dependent memory in the step-down passive avoidance test

Physiol Behav. 2010 Jun 16;100(4):297-304. doi: 10.1016/j.physbeh.2010.02.025. Epub 2010 Mar 19.

Abstract

In the present study, the effects of nitric oxide agents on WIN55, 212-2 induced state-dependent memory of passive avoidance task were examined in mice. One-trial step-down paradigm was used for the assessment of memory retention in adult male NMRI mice. Post-training intra-CA1 administration of CB1 and CB2 receptor agonists, WIN55, 212-2 (0.25, 0.5 and 1 microg/mouse), dose-dependently decreased memory retrieval. The memory impairment induced by post-training administration of WIN55, 212-2 (1 microg/mouse) was restored by pre-test administration of the same dose of the drug (1 microg/mouse, intra-CA1), showing the WIN55, 212-2 state-dependent memory. Single intra-CA1 administration of L-arginine (0.3, 1 and 3 microg/mouse) or L-NAME (0.3, 1 and 3 microg/mouse), 5 min pre-test could not alter memory retrieval. On the other hand, in the animals in which retrieval was impaired due to post-training administration of WIN55, 212-2 (1 microg/mouse), pre-test intra-CA1 administration of l-arginine (1 and 3 microg/mouse), but not L-NAME (0.3, 1 and 3 microg/mouse) 24h after training restored memory retrieval. Also, in the animals which received both post-training (1 microg/mouse) and pre-test injections of WIN55, 212-2 (1 microg/mouse), the injection of L-NAME (3 microg/mouse, intra-CA1), 2 min before pre-test administration decreased retrieval. Furthermore, in the animals under the influence of post-training administration of WIN55, 212-2 (1 microg/mouse), pre-test co-administration of non-effective doses of WIN55, 212-2 (0.25 microg/mouse) and L-arginine (0.3 and 1 microg/mouse), increased the restoration of memory by pre-test WIN55, 212-2. These findings may demonstrate the involvement of NO in state-dependent memory induced by intra-CA1 administration of WIN55, 212-2.

MeSH terms

  • Animals
  • Arginine / administration & dosage
  • Avoidance Learning / drug effects*
  • Benzoxazines / administration & dosage*
  • CA1 Region, Hippocampal / drug effects*
  • Cannabinoids / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Enzyme Inhibitors / administration & dosage
  • Exploratory Behavior / drug effects
  • Injections, Intraventricular
  • Male
  • Memory / drug effects*
  • Memory Disorders / chemically induced
  • Memory Disorders / parasitology
  • Mice
  • Mice, Inbred Strains
  • Morpholines / administration & dosage*
  • NG-Nitroarginine Methyl Ester / administration & dosage
  • Naphthalenes / administration & dosage*
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB2 / agonists

Substances

  • Benzoxazines
  • Cannabinoids
  • Enzyme Inhibitors
  • Morpholines
  • Naphthalenes
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Arginine
  • NG-Nitroarginine Methyl Ester